✦ LIBER ✦

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

✍ Scribed by Pei-xian Mao; Yi-lang Tang; Feng Jiang; Liang Shu; Xiuling Gu; Ming Li; Mincai Qian; Cui Ma; Philip B. Mitchell; Zhuo-ji Cai

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 163 KB
Volume: 25
Category: Article
ISSN: 1091-4269
DOI: 10.1002/da.20222

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A double-blind dose-finding study of rol

A double-blind dose-finding study of rolipram in patients with major depressive disorder

✍ E. H. Bennie; S. K. Chakravarti; C. M. B. Jarman; K. Khan; D. Master; G. H. Murr 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 460 KB 👁 2 views

Rolipram improves signal transmission in central noradrenergic neurones with a novel mechanism of action: enhanced noradrenaline (first messenger) synthesis and release, and inhibition of cAMP (second messenger) breakdown. Several comparative trials to prove antidepressant activity are under way. Re

A double-blind, multicenter trial compar

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

✍ Lesley M. Arnold; Yili Lu; Leslie J. Crofford; Madelaine Wohlreich; Michael J. D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract ## Objective To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder. ## Methods This study was a randomized, double‐blind, placebo‐controlled trial co

St. John's wort and Kava in treating maj

St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial

✍ Jerome Sarris; David J. Kavanagh; Gary Deed; Kerry M. Bone 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## Objective We report the first randomised controlled trial (RCT) using a combination of St. John's wort (SJW) and Kava for the treatment of major depressive disorder (MDD) with comorbid anxiety. ## Methods Twenty‐eight adults with MDD and co‐occurring anxiety were recruited for a d

Multicenter, randomized, double-blind, a

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

✍ Vladimir Coric; Howard H. Feldman; Dan A. Oren; Anantha Shekhar; Joseph Pultz; R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

Efficacy and safety of high-dose pravast

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

✍ James H. Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a place

Efficacy and safety of four doses of lum

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

✍ Schnitzer, Thomas J. ;Beier, Jannie ;Geusens, Piet ;Hasler, Paul ;Patel, Sanjay 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 3 views

## Abstract ## Objective To compare the efficacy and tolerability of the novel cyclooxygenase 2‐selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). ## Methods Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 m